Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1873 • ACR Convergence 2020
The Changing Profile of Ankylosing Spondylitis in the Biologic Era
Lauren Ridley¹, Michael Weisman², Lianne Gensler³, Michael Ward⁴, Mark Hwang⁵, Amirali Tahanan⁶, MinJae Lee⁷, Mohammad Rahbar⁶, Mariko Ishimori⁸, Matthew Brown⁹ and John Reveille¹⁰, ¹McGovern Medical School at UTHealth, Houston, TX, ²Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³University of California San Francisco, San Francisco, CA, ⁴National Institutes of Health, Bethesda, MD, ⁵McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ⁶McGovern Medical School at UTHealth, Houston, ⁷UT Southwestern, Dallas, ⁸Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ¹⁰Department of Internal Medicine, University of Texas, Houston, TX
Background/Purpose: To compare disease characteristics, comorbidities, and medication utilization of 573 patients with ankylosing spondylitis (AS) with short (< 20 years) disease duration (from symptom…
Abstract Number: 1899 • ACR Convergence 2020
Life Expectancy a Swiss Cohort of Patients with Ankylosing Spondylitis: A 35-Year Follow-up Study
Zhixiu Li¹, Mohammad Khan², Sjef van der Linden³, Peter Villiger⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶, Matthew Brown⁷ and Muhammad Khan⁸, ¹Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ²Kent State University, Kent, OH, ³Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ⁴Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁸Case Western Reserve University, Cleveland OH, Westlake, OH
Background/Purpose: To investigate life expectancy of a Swiss cohort of patients with ankylosing spondylitis (AS) versus general population during 35 years of longitudinal follow up,…
Abstract Number: 0165 • ACR Convergence 2020
Work Disability and Predictors of Poor Work Outcome in Patients with Axial Spondyloarthritis
Elif Ediboglu¹, Dilek Solmaz², Hande Ece Oz³, Gokhan Kabadayı⁴, Haluk Cinaklı⁴, Eda Otman Akat³, Mustafa Ozmen⁴ and Servet Akar³, ¹Izmir Katip Celebi University, Izmir, Izmir, Turkey, ²Izmir Katip Celebi University, Department of Internal Medicine, Division of Rheumatology, Izmir, TURKEY, Izmir, Turkey, ³Izmir Katip Celebi University, Izmir, Turkey, ⁴Izmir Katip Celebi University, Izmir
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which may lead substantial functional limitation. The disease more commonly affects men in their third decade…
Abstract Number: 0886 • ACR Convergence 2020
Achievement of Partial Remission and Inactive Disease in Upadacitinib-Treated Patients with Ankylosing Spondylitis
Atul Deodhar¹, Andrew Östör², Anna Maniccia³, Fabiana Ganz⁴, Tianming Gao³, Alvina D. Chu⁵ and Denis Poddubnyy⁶, ¹Oregon Health & Science University, Portland, OR, ²Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., Baar, Switzerland, ⁵AbbVie, North Chicago, IL, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Assessment of SpondyloArthritis international Society (ASAS) response criteria and AS Disease Activity Score (ASDAS) are both commonly used, rigorous composite indices consisting of components…
Abstract Number: 1319 • ACR Convergence 2020
Disease Activity and Mental Health of as Patients: A Cross-section Study with Self-assessments Based on Smart System of Disease Management (SSDM) Mobile Tools
Hui Song¹, Hua Wei², Miaojia Zhang³, Lijun Wu⁴, Zhenbiao Wu⁵, Aichun Chu⁶, Bei Wang⁷, Wenqiang Fan⁸, Xiaohan Wang⁹, Xiaoqi Chen¹⁰, Henglian Wu¹¹, Wenyu Zhou¹², Fei Xiao¹³, Hui Xiao¹⁴, Yuhua Jia¹³, Bing Wu¹³ and Jing Lu¹⁵, ¹Beijing Jishuitan Hospital, Beijing, China (People's Republic), ²Northern Jiangsu People's Hospital, Yangzhou, China (People's Republic), ³Jiangsu Province Hospital, The first affiliated hospital of Nanjing medical university, Nanjing, China (People's Republic), ⁴People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China (People's Republic), ⁵The First Affiliated Hospital of The Air Force Medical University, Xi＇an, Shanxi, China (People's Republic), ⁶Remin Hospital of Wuhan University Hubei General Hospital, Wuhan, China (People's Republic), ⁷Beijing Hospital of Traditional Chinese Medicine, Beijing, China (People's Republic), ⁸Central Hospital of XinXiang, Xinxiang, China (People's Republic), ⁹Anyang district hospital, Anyang, Henan, China (People's Republic), ¹⁰Zhongnan Hospital of Wuhan University, Wuhan, China (People's Republic), ¹¹Dongguan Donghua Hospital, Dongguan, Guangdong, China (People's Republic), ¹²Wuhan No. 4 Hospital, Wuhan, China (People's Republic), ¹³Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁴Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹⁵First Affiliated Hospital of China Medical University, Shenyang, China (People's Republic)
Background/Purpose: WHO survey showed that the prevalence of anxiety and depression in Chinese population and Chinese patients with chronic diseases were between 3.1% - 4.2%…
Abstract Number: 1477 • ACR Convergence 2020
Adherence in Patients with Chronic Rheumatic Diseases Treated with Biological and Synthetic Targeted Therapies During COVID-19 Pandemic
Patricia Castro Pérez¹, Alberto Onteniente González¹, Angel Aragón Díez¹, Angel Gallegos Cid¹, Jesús Garcia-Arroba Muñoz¹ and Jose Manuel Rodriguez heredia¹, ¹Hospital de Getafe, Madrid, Spain
Background/Purpose: Adherence to treatments for chronic rheumatic diseases is influenced by many factors, including the patient's belief in the development of adverse effects such as…
Abstract Number: 1874 • ACR Convergence 2020
Differences Between Men and Women in the Patient Pathways to Diagnosis of Ankylosing Spondylitis
Mark Hwang¹, Martin Rozycki², Theresa Arndt², Esther Yi³ and Michael Weisman⁴, ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²HVH Precision Analytics, LLC, Wayne, PA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Healthcare claims databases can be used to identify patients with ankylosing spondylitis (AS) prior to diagnosis. This study explores differences in pathways to AS…
Abstract Number: 1900 • ACR Convergence 2020
The Clinical and the Functional Impact of Central Sensitization on Patients with Axial Spondyloarthritis
Feyza Nur Yücel¹ and Mehmet Tuncay Duruöz², ¹Marmara University School of Medicine PMR Department, Istanbul, Turkey, ²Marmara University School of Medicine, PMR Department, Rheumatology Division, Istanbul, Turkey
Background/Purpose: To evaluate the impact of central sensitization (CS) on axial spondyloarthritis (AxSpA) patients’ clinical and functional situation and quality of life.Methods: Subjects with axSpA…
Abstract Number: 0341 • ACR Convergence 2020
Metabolomics Profiling of Human Serum for Discovering Biomarkers to Diagnose Psoriatic Arthritis and Ankylosing Spondylitis with High Specificity
Wei Han¹, Xiaohang Wang¹, Liang Li¹, Stephanie Wichuk², Edna Hutchings³, Rana Dadashova³, Joel Paschke³ and Walter Maksymowych², ¹Department of Chemistry, University of Alberta, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: In this work, we applied a high-performance chemical isotope labeling (CIL) LC-MS platform to search for biomarker candidates of PsA and AS in human…
Abstract Number: 0892 • ACR Convergence 2020
Long-Term Safety Profile of Ixekizumab Treatment in Patients with Axial Spondyloarthritis
Sergio Schwartzman¹, David Sandoval², Andris Kronbergs², Jeffrey Lisse³, Himanshu Patel³, Wen Xu³, Soyi Liu-Leage³, Marina Magrey⁴, Helena Marzo-Ortega⁵ and Denis Poddubnyy⁶, ¹Weill Cornell Medical College, New York, NY, ²Eli Lilly and Company, Indianapolis, ³Eli Lilly and Company, Indianapolis, IN, ⁴Case Western Reserve University School of Medicine, Cleveland, OH, ⁵The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, has demonstrated efficacy in the treatment of the axial spondyloarthritis (axSpA) spectrum (ankylosing spondylitis and…
Abstract Number: 1323 • ACR Convergence 2020
Pregnancy in Axial Spondyloarthropathy: A Systematic Review & Meta-Analysis
Sinead Maguire¹, Tom O'Dwyer², Fiona Wilson³, David Mockler³ and Finbar O'Shea¹, ¹St James' Hospital, Dublin, Ireland, ²Independent Researcher, Dublin, Ireland, ³Trinity College Dublin, Dublin, Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) is an inflammatory arthritis affecting the sacroiliac joints and the spine. Although this chronic condition affects a wide range of ages,…
Abstract Number: 1517 • ACR Convergence 2020
Metabolic Regulation of Type 3 Innate Lymphoid Cells by Intestinal Bacteria-Derived Indoles in Ankylosing Spondylitis
Adam Berlinberg¹, Adam Lefferts², Emilie Regner³, Andrew Stahly⁴ and Kristine Kuhn⁴, ¹University of Colorado, Denver, CO, ²University of Colorado, Anschutz Medical Campus, Denver, CO, ³University of California San Francisco, San Francisco, CA, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Intestinal microbial dysbiosis, intestinal inflammation, and Th17 immunity are all linked to the pathophysiology of ankylosing spondylitis (AS); however, the mechanisms linking them remain…
Abstract Number: 1875 • ACR Convergence 2020
Heterogeneity Amongst Men and Women with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Zhixiu Li¹, Muhammad Khan², Mohammad Khan³, Peter Villiger⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶, Sjef van der Linden⁷ and Matthew Brown⁸, ¹Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ²Case Western Reserve University, Cleveland OH, Westlake, OH, ³Kent State University, Kent, OH, ⁴Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ⁸Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axial disease (nr-axSpA). Our purpose was to investigate genetic heterogeneity of clinically diagnosed axSpA.Methods:…
Abstract Number: 1904 • ACR Convergence 2020
Clinical Features of Patients with Active Ankylosing Spondylitis Who Did Not Respond to Adalimumab but Responded to Ixekizumab: A Post-hoc Analysis
Xenofon Baraliakos¹, Rebecca Bolce², David Sandoval², Soyi Liu-Leage³, Vladimir Geneus³, David Adams³, Atul Deodhar⁴, Jessica Walsh⁵ and Joachim Sieper⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Eli Lilly and Company, Indianapolis, ³Eli Lilly and Company, Indianapolis, IN, ⁴Oregon Health & Science University, Portland, OR, ⁵University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Biologic therapy is recommended in patients with active ankylosing spondylitis (AS) despite adequate trial of NSAIDs. Biologic treatment in AS are currently limited to…
Abstract Number: 0350 • ACR Convergence 2020
The Impact of Age and Time Since Diagnosis on Response to Treatment with Secukinumab in Pooled Week 52 Data from 4 Phase 3 Studies in Patients with Ankylosing Spondylitis
Atul Deodhar¹, Philip Mease², Paula Machado³, Effie Pournara⁴, Xiangyi Meng³, Vibeke Strand⁵ and Marina Magrey⁶, ¹Oregon Health & Science University, Portland, OR, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁶Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease involving the sacroiliac joints and spine and associated with pain, stiffness, and disability.1 A previous analysis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].